PDCD1LG2 and hepatocellular carcinoma: We also explored correlations between NUSAP1 and four immune modulators (CTLA4, PD1, PD-L1, and PD-L2), and we found that HCC patients in the low expression group of NUSAP1 might present with a better response for CTLA4 immunotherapy.